New drug MK-2828 tested in kidney patients – first look at dosing
NCT ID NCT07348237
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a single dose of the drug MK-2828 in 24 people with different levels of kidney function, including those with severe kidney failure or on dialysis. The goal is to measure how the drug moves through the body over time and compare it to healthy volunteers. No treatment benefit is expected; the results will guide future dosing recommendations.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-2828
What this could lead to
If successful, this study will help doctors understand how to dose MK-2828 safely for people with kidney problems.
What could go wrong
This is a very early, small Phase 1 trial focused on drug levels, not on treating disease. It may not lead to any treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Floridian Clinical Research ( Site 0001)
RECRUITINGMiami Lakes, Florida, 33016, United States
Contact Phone: •••-•••-••••
-
Orlando Clinical Research Center ( Site 0002)
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
-
Panax Clinical Research ( Site 0003)
RECRUITINGMiami Lakes, Florida, 33014, United States
Contact Phone: •••-•••-••••